Table 2.
Comparisons of whole ovarian IHC staining of markers assessed in PCOS and control mice ovaries
| Marker | PCOS/ Controls | N | Mean Total Area (Sum Area) (μm2)(× 103) | Percentage of Staining (Area fraction ROI) (%) | Average Intensity of Staining (Mean Colour Intensity) |
|---|---|---|---|---|---|
| PAI-1 | Controls | 6 | 281 ± 264 | 7.86 ± 5.96 | 178.27 ± 6.79 |
| PCOS | 6 | 323 ± 266 | 13.90 ± 10.57 | 177.07 ± 8.40 | |
| tPA | Controls | 6 | 17 ± 22 | 0.63 ± 0.79 | 172.90 ± 6.02 |
| PCOS | 6 | 8 ± 10 | 0.29 ± 0.38 | 169.73 ± 4.20 | |
| uPA | Controls | 6 | 227 ± 174 | 7.61 ± 5.72 | 164.58 ± 6.57 |
| PCOS | 6 | 155 ± 125 | 6.86 ± 5.37 | 163.43 ± 4.04 | |
| Plasminogen/Plasmin NBP2–19859 | Controls | 6 | 271 ± 183 | 7.21 ± 4.09 | 178.95 ± 3.18 |
| PCOS | 6 | 193 ± 79 | 8.64 ± 3.53 | 180.70 ± 6.25 | |
| Plasminogen NB300–544 | Controls | 6 | 1147 ± 1092 | 38.93 ± 23.14 | 165.16 ± 5.09 |
| PCOS | 6 | 936 ± 646 | 41.10 ± 23.38 | 162.72 ± 8.75 |
Mean ± SD are represented for all values. PAI-1, plasminogen activator inhibitor-1; tPA, tissue plasminogen activator; uPA, urokinase plasminogen activator; ROI, region of interest; N = number of mice ovarian sections or number of mice evaluated (one ovarian section per mouse)